Valente Angélica M M, Reis André F, Machado Daisy M, Succi Regina C M, Chacra Antonio R
Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP.
Arq Bras Endocrinol Metabol. 2005 Dec;49(6):871-81. doi: 10.1590/s0004-27302005000600004. Epub 2006 Mar 16.
The introduction of highly active antiretroviral therapy (HAART) has reduced morbidity and mortality in patients infected with the human immunodeficiency virus (HIV). However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. Treatment with antiretroviral agents--protease inhibitors in particular--has uncovered a syndrome of abnormal fat redistribution, impaired glucose metabolism, insulin resistance and dyslipidemia, collectively termed lipodystrophy syndrome (SLHIV). Nowadays, no clinical guidelines are available for the prevention or treatment of SLHIV, and its cause have yet to be totally elucidated. This review emphasizes the clinical features and the data from previous studies about the SLHIV taking into account that a better understanding of this syndrome for HIV specialists, cardiologists and endocrinologists is fundamental for the disease control.
高效抗逆转录病毒疗法（HAART）的引入降低了人类免疫缺陷病毒（HIV）感染者的发病率和死亡率。然而，由于依从性问题和毒性作用，联合用药方案的长期治疗可能难以维持。抗逆转录病毒药物治疗，尤其是蛋白酶抑制剂治疗，发现了一种脂肪重新分布异常、葡萄糖代谢受损、胰岛素抵抗和血脂异常的综合征，统称为HIV脂肪代谢障碍综合征（SLHIV）。目前，尚无预防或治疗SLHIV的临床指南，其病因也尚未完全阐明。本综述强调了SLHIV的临床特征以及以往研究的数据，考虑到对于HIV专家、心脏病专家和内分泌专家而言，更好地了解该综合征对于疾病控制至关重要。
